May 8, 2009

Phase 3 Data On VIVUS' Qnexa To Be Presented At 17th European Congress On Obesity

VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that data from the phase 3 EQUATE trial (OB-301) of Qnexa™ in obese patients will be presented at the 17th annual European Congress on Obesity (ECO) in Amsterdam, The Netherlands.

Filed under 12163 by

Spread the word

del.icio.us Digg Furl Reddit Ask BlinkList blogmarks Google Ma.gnolia Netscape Rojo Shadows Simpy Socializer Spurl StumbleUpon Tailrank Technorati Windows Live Wists Yahoo! Help

Permalink • Print • Comment

Track this entry

RSS BlogPulse

RSS Technorati Cosmos

Leave a Comment